Ranbaxy's US unit gets USFDA's establishment inspection report

The facility was under FDA scanner since December 2012 for alleged violation of manufacturing norms

The US health regulator has given Ranbaxy Laboratories' American arm Ohm Laboratories Inc a report indicating closure of inspection of its plant.

Ohm Laboratories Inc said it had received a copy from the US Food and Drug Administration (USFDA) of its Establishment Inspection Report (EIR) for its December 2012 inspection of the plant at New Brunswick in US.

This facility was under FDA scanner since the December 2012 for alleged violation of manufacturing norms.

The company, however, did not disclose the contents of the EIR which determines that the inspection has been closed.

Currently Ohm Laboratories plant is the only one from which Ranbaxy continues supplying drugs to the US market as drugs manufactured in its other facilities at Paonta Sahib, Dewas and Mohali in India have been  banned on account of non compliance of current good manufacturing practise (CGMP).

Acquired by Ranbaxy in 1995, Ohm Laboratories manufactures prescription and over-the-counter (OTC) drugs in solid dose forms (capsules and tablets) and is US Drug Enforcement Agency (DEA) approved to manufacture controlled substances.

Shares of Ranbaxy Laboratories today closed at Rs 399.20 per scrip, up 1.54% from their previous close.